{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sacco K"],"funding":["Intramural NIH HHS","NCI NIH HHS"],"pagination":["1050-1062"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9119950"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["28(5)"],"pubmed_abstract":["Pediatric Coronavirus Disease 2019 (pCOVID-19) is rarely severe; however, a minority of children infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might develop multisystem inflammatory syndrome in children (MIS-C), with substantial morbidity. In this longitudinal multi-institutional study, we applied multi-omics (analysis of soluble biomarkers, proteomics, single-cell gene expression and immune repertoire analysis) to profile children with COVID-19 (n = 110) and MIS-C (n = 76), along with pediatric healthy controls (pHCs; n = 76). pCOVID-19 was characterized by robust type I interferon (IFN) responses, whereas prominent type II IFN-dependent and NF-κB-dependent signatures, matrisome activation and increased levels of circulating spike protein were detected in MIS-"],"journal":["Nature medicine"],"pubmed_title":["Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19."],"pmcid":["PMC9119950"],"funding_grant_id":["ZIA AI001265","ZIA AI001270","75N91019D00024"],"pubmed_authors":["Vakkilainen S","Mackey J","Sacco K","Truong M","Astudillo C","Hu S","Hulett T","Kuram V","Oler AJ","de Jesus AA","Rastegar A","Gerstbacher D","Bosticardo M","Guarino A","Rey-Jurado E","Gonzalez R","Bhuyan F","Licari A","Licciardi F","Lack J","Burbelo PD","Sottini A","Martins AJ","Su HC","NIAID Immune Response to COVID Group","Shyu C","Rosen LB","Poli MC","Dalgard CL","Chen J","Castagnoli R","Kaplan IM","Fink DL","Kawai T","Xirasagar S","Matthews H","De Filippo M","Notarangelo LD","Ramenghi U","Chile MIS-C Group","Lo Vecchio A","Oikonomou V","Oguz C","Stack MA","Kuhns DB","Discepolo V","Tsang JS","Nambiar M","Magliocco M","Cohen JI","Cheng X","Espinosa Y","Biondi A","Pavia Pediatric COVID-19 Group","Mato S","Vial C","Palterer B","Marseglia GL","Shaw E","Bansal NM","Montealegre Sanchez GA","Holland SM","Delmonte OM","Kaladi K","Askenazi M","Pala F","Barnett J","Barron K","Snow AL","Cheng A","Waingankar V","Pinera C","Goldbach-Mansky R","Mudunuri U","Snyder TM","Samuel S","Sellers BA","Eisenstein EM","Imberti L","Montagna L","Vakkilainen MS","Zhang Y","Danielson JJ","Dobbs K","Lionakis MS","Weber S","Montagna D","Votto M","Alehashemi S","Liu C"],"additional_accession":[]},"is_claimable":false,"name":"Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19.","description":"Pediatric Coronavirus Disease 2019 (pCOVID-19) is rarely severe; however, a minority of children infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might develop multisystem inflammatory syndrome in children (MIS-C), with substantial morbidity. In this longitudinal multi-institutional study, we applied multi-omics (analysis of soluble biomarkers, proteomics, single-cell gene expression and immune repertoire analysis) to profile children with COVID-19 (n = 110) and MIS-C (n = 76), along with pediatric healthy controls (pHCs; n = 76). pCOVID-19 was characterized by robust type I interferon (IFN) responses, whereas prominent type II IFN-dependent and NF-κB-dependent signatures, matrisome activation and increased levels of circulating spike protein were detected in MIS-","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2026-05-31T16:01:20.2Z","creation":"2025-02-19T01:27:55.207Z"},"accession":"S-EPMC9119950","cross_references":{"pubmed":["35177862"],"doi":["10.1038/s41591-022-01724-3"]}}